论文部分内容阅读
目的:探讨参麦联合米力农治疗难治性心力衰竭患者的临床效果。方法:选取在我院接受治疗的难治性心力衰竭患者74例,随机将所有的患者分为对照组和研究组各37例。在常规治疗基础上,对照组选用米力农进行治疗,研究组则采用参麦与米力农联合治疗。结果:治疗结束后,对照组的总有效率为81.1%,研究组的总有效率为91.9%,两组比较差异显著,具有统计学意义(p<0.05)。讨论:采用参麦与米力农中西两种药物联合治疗难治性心力衰竭,可以有效产生协同和互补作用,疗效明显优于单纯用药,安全可靠,具有临床应用价值。
Objective: To investigate the clinical effects of Shenmai combined with Milrinone in patients with refractory heart failure. Methods: Totally 74 patients with refractory heart failure treated in our hospital were randomly divided into the control group and the study group, with 37 cases in each group. On the basis of routine treatment, the control group was treated with Milrinone, while the study group was treated with Shenmai and Milrinone. Results: After the treatment, the total effective rate was 81.1% in the control group and 91.9% in the study group. There was significant difference between the two groups (p <0.05). Discussion: The use of Shenmai and Milinone two drugs combined treatment of refractory heart failure, can effectively produce synergies and complementary effects, the effect was significantly better than simple medication, safe, reliable, and has clinical value.